BioVie (NASDAQ:BIVI) CEO Cuong Do Acquires 15,210 Shares

BioVie Inc. (NASDAQ:BIVI) CEO Cuong Do acquired 15,210 shares of the firm’s stock in a transaction on Thursday, August 27th. The stock was purchased at an average price of $2.08 per share, with a total value of $31,636.80. Following the purchase, the chief executive officer owned 16,117 shares in the company, valued at approximately $33,523.36. The trade was a 1,676.96% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

BioVie Stock Performance

Shares of BioVie stock traded down $0.03 during mid-day trading on Friday, hitting $2.16. 483,161 shares of the stock were exchanged, compared to its average volume of 14,005,157. BioVie Inc. has a 12 month low of $0.82 and a 12 month high of $3.79. The company has a 50-day simple moving average of $1.70 and a 200 day simple moving average of $1.53. The company has a market capitalization of $18.25 million, a P/E ratio of -0.69 and a beta of 0.60.

BioVie (NASDAQ:BIVI) last released its earnings results on Wednesday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.18).

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on BIVI. Weiss Ratings restated a “sell (e+)” rating on shares of BioVie in a research note on Friday, July 17th. Wall Street Zen upgraded BioVie to a “sell” rating in a research note on Saturday, July 18th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, BioVie currently has an average rating of “Sell”.

Institutional Investors Weigh In On BioVie

Large investors have recently modified their holdings of the stock. XTX Topco Ltd purchased a new stake in shares of BioVie during the 4th quarter worth approximately $25,000. Two Sigma Investments LP bought a new position in BioVie during the third quarter valued at $62,000. Squarepoint Ops LLC bought a new position in BioVie during the third quarter valued at $63,000. NewEdge Advisors LLC increased its position in BioVie by 283.7% in the first quarter. NewEdge Advisors LLC now owns 54,100 shares of the company’s stock worth $53,000 after buying an additional 40,000 shares during the last quarter. Finally, Jane Street Group LLC purchased a new stake in BioVie in the second quarter worth $57,000. Hedge funds and other institutional investors own 4.59% of the company’s stock.

About BioVie

BioVie Inc is a clinical?stage biopharmaceutical company focused on developing novel therapies for chronic liver diseases and associated neurological complications. The company’s research and development efforts center on candidates designed to address serious unmet medical needs in hepatic encephalopathy and other liver?related disorders. BioVie advances its pipeline through controlled clinical trials and regulatory interactions in North America.

The company’s lead product candidate, BIV201, is undergoing Phase 2 clinical evaluation for the treatment of hepatic encephalopathy, a life?threatening condition marked by elevated neurotoxins in patients with advanced liver disease.